Pharma channel feed

No­var­tis finds its next mass-mar­ket oph­thal­mol­o­gy drug can­di­date at a small vir­tu­al biotech with a glob­al view

9 years ago
Startups

Study high­lights the FDA’s speed in ap­prov­ing can­cer drugs as a new com­mish looks to rev up re­views

9 years ago

Za­vante hits the fin­ish line, de­clar­ing a piv­otal win for its an­tibi­ot­ic now head­ed (even­tu­al­ly) to the FDA

9 years ago

Much crit­i­cized Mallinck­rodt bows out of PhRMA ahead of some tight­ened re­stric­tions on mem­ber­ship

9 years ago

Scott Got­tlieb aced his con­fir­ma­tion hear­ing, vow­ing to main­tain R&D gold stan­dard

9 years ago

Take­da part­ners with an up­start drugs-from-bugs mi­cro­bio­me play­er in­spired by a fe­cal trans­plan­ta­tion biz

9 years ago
Startups

Bris­tol-My­ers joins the IDO rush with its own in-house com­bo pro­gram for Op­di­vo

9 years ago
R&D

In a first for deuter­at­ed drugs, FDA (fi­nal­ly) OKs Te­va’s would-be Hunt­ing­ton’s block­buster Auste­do

9 years ago

#AACR17 roundup: Bris­tol-My­ers, Mer­ck KGaA and Pfiz­er in the spot­light, mark­ing progress with check­points

9 years ago
R&D

Hit with a tri­al fail­ure, Agenus brings out the ax to chop staff, re­or­ga­nize

9 years ago
R&D

FDA nom­i­na­tion in hand, Got­tlieb pre­pares to dis­en­tan­gle him­self from a long list of bio­phar­ma jobs and in­vest­ments

9 years ago

Why wait? Trump mounts an ear­ly raid on NIH’s ’17 bud­get in search of some spend­ing mon­ey

9 years ago
People
R&D

Megablock­buster day for Roche too as MS game-chang­er Ocre­vus gets a green light at the FDA

9 years ago

Ver­tex is re­or­ga­niz­ing and con­sol­i­dat­ing R&D, shut­ter­ing a site in Cana­da

9 years ago
R&D

Re­gen­eron and Sanofi land the big one, win­ning FDA ap­proval for their megablock­buster hope­ful Dupix­ent

9 years ago

Take that Ed­i­tas: CRISPR Ther­a­peu­tics and col­leagues win a Eu­ro­pean round in the IP tug-of-war over gene edit­ing tech

9 years ago

Swiss an­ti­body shop Num­ab strikes an im­muno-on­col­o­gy dis­cov­ery deal with Japan’s Ono

9 years ago

FDA OKs Tesaro’s ni­ra­parib for ovar­i­an can­cer, hand­ing the biotech a big win on the la­bel

9 years ago

Pumped by an ear­ly glimpse of ef­fi­ca­cy, Newron charts a piv­otal course for schiz­o­phre­nia drug

9 years ago
R&D

Am­gen trig­gers yet an­oth­er re­vamp, mov­ing re­searchers to two big hubs

9 years ago

Eli Lil­ly un­veils an $850M makeover as Trump pounds the ta­ble for new US jobs, man­u­fac­tur­ing

9 years ago
People
R&D

No­var­tis lat­er­als two PhII an­ti-ag­ing drugs to a PureTech start­up, grab­bing an eq­ui­ty stake

9 years ago

Sleuthy Google up­start Cal­i­co forges a rare biotech col­lab­o­ra­tion on ag­ing with No­var­tis-backed C4

9 years ago
R&D

Pfiz­er, Mer­ck KGaA score a land­mark FDA OK for check­point con­tender avelum­ab

9 years ago
First page Previous page 329330331332333334335 Next page Last page
A service from the Financial Times